Net profit of Cohance Lifesciences declined 46.50% to Rs 74.08 crore in the quarter ended September 2025 as against Rs 138.47 crore during the previous quarter ended September 2024. Sales declined 7.98% to Rs 555.57 crore in the quarter ended September 2025 as against Rs 603.77 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales555.57603.77 -8 OPM %21.7734.01 - PBDT127.79211.95 -40 PBT83.77174.16 -52 NP74.08138.47 -47 Powered by Capital Market - Live News

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live News

Cohance Lifesciences announced that the United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at its API manufacturing facility (API Unit 1) located at Jaggaiahpet, Andhra Pradesh. The inspection was conducted from 08 September 2025 to 11 September 2025 and concluded with zero Form 483 observations. Powered by Capital Market - Live News

Net profit of Cohance Lifesciences declined 35.15% to Rs 48.88 crore in the quarter ended June 2025 as against Rs 75.37 crore during the previous quarter ended June 2024. Sales rose 12.55% to Rs 549.31 crore in the quarter ended June 2025 as against Rs 488.08 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales549.31488.08 13 OPM %20.3925.63 - PBDT116.00134.31 -14 PBT70.86103.03 -31 NP48.8875.37 -35 Powered by Capital Market - Live News

The Board of Cohance Lifesciences has appointed Yann D`Herve as Chief Executive Officer - CDMO Business, and Senior Management Personnel of the Company, with effect from 01 August 2025. Yann will be based out of New Jersey, United States of America. Powered by Capital Market - Live News